Clinical Trials

Neoplasm Metastasis, Cholangiocarcinoma

NCT04504331 2026-02-12

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Phase 1 Terminated

4 enrolled 11 charts

Breast

Breast Neoplasms

NCT02657486 2026-02-09

BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

Phase NA Completed

4 enrolled

Phase EARLY_PHASE1 Terminated

Urinary Bladder Neoplasms

NCT04424966 2025-10-24

Infigratinib in Recurrent High-Grade Glioma Patients

7 enrolled 18 charts

CNS

Glioblastoma, Glioma

NCT04228042 2025-01-01

Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer

Phase 1/2 Terminated

15 enrolled 10 charts

Renal Pelvis and Ureter Urothelial Carcinoma

NCT06206278 2024-08-14

Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

6 enrolled

Stomach Neoplasms

NCT03773302 2024-05-08

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Phase 3 Terminated

48 enrolled 26 charts

Cholangiocarcinoma

NCT04197986 2024-03-13

PROOF302

Phase 3 Terminated

39 enrolled 31 charts

Upper Tract Urothelial Carcinomas

NCT02159066 2024-03-05

LOGIC-2

Phase 2 Completed

158 enrolled 40 charts

Dermatologic

Melanoma

NCT05514912 2023-12-26

Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial

Phase 2 Withdrawn

Cholangiocarcinoma

NCT05510427 2023-08-15

Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification

Phase 1 Withdrawn

Liver Neoplasms, Cholangiocarcinoma

NCT02150967 2023-07-03

A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

143 enrolled 25 charts 1 FDA

Cholangiocarcinoma

NCT05222165 2023-02-23

NEWEL

Phase 1/2 Withdrawn

CNS

Central Nervous System Neoplasms

NCT04972253 2022-08-10

(BLASST)-3

Phase 1 Withdrawn

Acrocephalosyndactylia, Urinary Bladder Neoplasms

NCT05019794 2022-06-27

FGFR

Phase 2 Unknown

80 enrolled

Acrocephalosyndactylia, Stomach Neoplasms

NCT03510455 2021-04-08

BGJ398 for the Treatment of Tumor-Induced Osteomalacia

4 enrolled 28 charts

Oncogenic osteomalacia, Hypophosphatemia

NCT01928459 2020-12-09

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

Phase 1 Completed

62 enrolled

Breast

Acrocephalosyndactylia, Breast Neoplasms

NCT01697605 2020-12-08

A Phase I Study of Oral BGJ398 in Asian Patients

Phase 1 Completed

9 enrolled

Tumor With Alterations of the FGF-R

NCT02257541 2020-03-30

BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Phase 1/2 Completed

16 enrolled 14 charts

GastrointestinalSarcoma

Advanced Gastrointestinal Stromal Tumor (GIST)

NCT01975701 2019-12-04

A Phase 2 Study of BGJ398 in Patients With Recurrent GBM

Phase 2 Completed

26 enrolled 10 charts

CNS

Glioblastoma

NCT01004224 2019-10-04

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Phase 1 Completed

208 enrolled

GenitourinaryThoracic

Urinary Bladder Neoplasms, Lung Neoplasms

NCT02160041 2019-06-18

CBGJ398XUS04

Other hematologic neoplasm

84 enrolled 15 charts

Hematologic Neoplasms

NCT02706691 2019-04-16

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

1 enrolled 8 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Neoplasms, Papillomavirus Infections

NCT02575508 2016-05-20

Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer

Phase 1/2 Withdrawn